What Indaptus Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 19,125,000 |
| Disposed | 0 | 0 |
| Net activity | +0 | +19,125,000 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ben-Tzvi Avraham | Director | Jan 20 | Grant / award · A | +25,000 | — | — | 25,100 |
| Meckler Jeffrey A | Co-Chief Executive Officer | Dec 22 | Grant / award · A | +216,617 | $2.03 | +$440K | 229,929 |
| Sassi Nir | Chief Financial Officer | Dec 22 | Grant / award · A | +26,758 | $2.03 | +$54.3K | 26,758 |
| Linscott Walt Addison | Chief Operating Officer | Dec 22 | Grant / award · A | +54,421 | $2.03 | +$110K | 54,426 |
| Newman Michael James | CSO and Director | Dec 22 | Grant / award · A | +52,204 | $2.03 | +$106K | 101,074 |
| Meckler Jeffrey A | Chief Executive Officer | Jul 27 | Grant / award · A | +6,068 | $8.30 | +$50.4K | 13,312 |
| Meckler Jeffrey A | CEO and Director | Nov 25 | Grant / award · A | +42,553 | $1.18 | +$50K | 202,859 |
| Meckler Jeffrey A | CEO and Director | Aug 08 | Grant / award · A | +84,932 | $1.83 | +$155K | 160,306 |
| Anderson Glen R. | 10% owner | Aug 14 | Open-market buy · P | +23,934 | $2.34 | +$56K | 1,190,400 |
| Anderson Glen R. | 10% owner | Aug 11 | Open-market buy · P | +35,064 | $2.12 | +$74.3K | 1,166,466 |
| Anderson Glen R. | 10% owner | Aug 10 | Open-market buy · P | +44,354 | $1.94 | +$86K | 1,131,402 |
| Litchev Boyan Vesselinov | Chief Medical Officer | Dec 01 | Open-market buy · P | +500 | $1.87 | +$935 | 1,150 |
| Litchev Boyan Vesselinov | Chief Medical Officer | Nov 22 | Open-market buy · P | +500 | $1.83 | +$915 | 650 |
| Meckler Jeffrey A | CEO and Director | Nov 21 | Open-market buy · P | +9,600 | $1.90 | +$18.2K | 75,374 |
| Meckler Jeffrey A | CEO and Director | Nov 18 | Open-market buy · P | +400 | $1.76 | +$705 | 65,774 |
| Meckler Jeffrey A | CEO and Director | Sep 08 | Open-market buy · P | +10,308 | $2.80 | +$28.9K | 65,374 |
| Meckler Jeffrey A | CEO and Director | Sep 07 | Open-market buy · P | +8,632 | $2.57 | +$22.2K | 55,066 |
| Linscott Walt Addison | Chief Business Officer | Sep 07 | Open-market buy · P | +150 | $2.62 | +$393 | 150 |
| Meckler Jeffrey A | CEO and Director | Sep 06 | Open-market buy · P | +1,060 | $2.44 | +$2.59K | 46,434 |
| Meckler Jeffrey A | CEO and Director | Jun 06 | Open-market buy · P | +19,727 | $2.63 | +$51.9K | 45,374 |
Loading...